Report on Phase II Clinical Study of Marshall Edwards' Phenoxodiol in Prostate Cancer to Be Presented at ASCO
May 21 2010 - 9:00AM
Marketwired
Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase
II study of oral phenoxodiol in castrate and non-castrate prostate
cancer patients with associated cytokine changes" by Dr Kevin Kelly
at the Yale School of Medicine Department of Medical Oncology, is
now available at www.asco.org (abstract # 4661). The findings from
this study in which safety and efficacy of phenoxodiol in both
early (pre-metastatic) and late stage disease has been compared
will be presented June 7, 2010 at the Annual Meeting of the
American Society of Clinical Oncology (ASCO), Chicago, Illinois.
About phenoxodiol:
Phenoxodiol is being developed as a chemosensitizing agent in
combination with platinum drugs for late stage, chemoresistant
ovarian cancer and as a monotherapy for prostate and cervical
cancers. It is believed to have a unique mechanism of action,
binding to cancer cells via a cell membrane oxidase, causing
disturbances in expression of proteins necessary for cancer cell
survival and responsible for the development of drug
resistance.
In cancer cells, phenoxodiol appears to selectively inhibit the
regulator known as S-1-P (sphingosine-1-phosphate) that is
overexpressed in cancer cells. In response to phenoxodiol, the
S-1-P content in cancer cells is decreased, with a consequent
decrease in expression of the pro-survival proteins XIAP and FLIP,
inducing cancer cell death via caspase expression and promoting
sensitivity to chemotherapeutics. Phenoxodiol has received Fast
Track status from the FDA to facilitate its development as a
therapy for recurrent ovarian and prostate cancers. Phenoxodiol is
an investigational drug and, as such, is not commercially
available. Under U.S. law, a new drug cannot be marketed until it
has been investigated in clinical trials and approved by FDA as
being safe and effective for the intended use.
About Marshall Edwards, Inc.
Marshall Edwards, Inc. is a specialist oncology company focused
on the clinical development of novel anti-cancer therapeutics.
These derive from a flavonoid technology platform, which has
generated a number of novel compounds characterized by broad
ranging activity against a range of cancer cell types with few side
effects. The combination of anti-tumor cell activity and low
toxicity is believed to be a result of the ability of these
compounds to target an enzyme present in the cell membrane of
cancer cells, thereby inhibiting the production of pro-survival
proteins within the cell. Marshall Edwards has licensed rights from
Novogen Limited (ASX: NRT) (NASDAQ: NVGN) to bring four oncology
drugs -- phenoxodiol, triphendiol, NV-143 and NV-128 -- to market
globally.
Marshall Edwards is majority owned by Novogen Limited, an
Australian biotechnology company that is specializing in the
development of therapeutics based on a flavonoid technology
platform. Novogen is developing a range of therapeutics across the
fields of oncology, cardiovascular disease and inflammatory
diseases. More information on phenoxodiol and on the Novogen group
of companies can be found at www.marshalledwardsinc.com and
www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
CONTACTS: Warren Lancaster +1-203-966-2556 (USA) Email
Contact
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024